Product news

Share this article:

The FDA approved Eli Lilly's osteoporosis drug Evista to reduce breast cancer risk in some postmenopausal women. Specifically, the FDA approved Evista to lower the risk of invasive breast cancer (the most common form of breast cancer) in two groups of women: postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer, Evista is only the second drug approved to reduce breast cancer risk (tamoxifen was the first). In the US, breast cancer is the No. 2 cause of women's cancer deaths (lung cancer is first). Breast cancer accounts for 26% of all cancers among US women.


Mylan Laboratories has received tentative approval from the FDA for its Abbreviated New Drug Application for topiramate capsules, 15 mg and 25 mg. Topiramate capsules are the generic version of Ortho McNeil Pharmaceuticals' Topamax sprinkle capsules which had US sales of approximately $46 million for the 12 months ending June 30, 2007.


The FDA has approved a high-dose regimen of Johnson & Johnson's antibiotic Levaquin to treat complicated urinary tract and kidney infections.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.